Developing vaccines in the era of genomics: a decade of reverse vaccinology  by Seib, K.L. et al.
Developing vaccines in the era of genomics: a decade of reverse
vaccinology
K. L. Seib, X. Zhao and R. Rappuoli
Novartis Vaccines and Diagnostics, Siena, Italy
Abstract
Vaccines have a significant impact on public health, and vaccinology in the era of genomics is taking advantage of new technologies to
tackle diseases for which vaccine development has so far been unsuccessful. Almost all existing vaccines were developed based on tradi-
tional vaccinology methods, which relied on empirical screening of a few candidates at a time, based on known features of the pathogen.
However, the ability to sequence a pathogen’s genome provides access to its entire antigenic repertoire. As such, genomics has cataly-
sed a shift in vaccine development towards sequence-based ‘Reverse Vaccinology’ approaches, which use high-throughput in silico
screening of the entire genome of a pathogen to identify genes that encode proteins with the attributes of good vaccine targets. Fur-
thermore, the increasing availability of genome sequences has led to the development and application of additional technologies to vac-
cine discovery, including comparative genomics, transcriptomics, proteomics, immunomics and structural genomics. Vaccine candidates
identified from a pathogen’s genome or proteome can then be expressed as recombinant proteins and tested in appropriate in vitro or
in vivo models to assess immunogenicity and protection. The process of reverse vaccinology has been applied to several pathogens,
including serogroup B Neisseria meningitidis, Streptococcus agalactiae, Streptococcus pyogenes, Streptococcus pneumoniae and pathogenic Esc-
herichia coli, and has provided scores of new candidate antigens for preclinical and clinical investigation. As novel genome-based technol-
ogies continue to emerge, it is expected that new vaccines for unmet diseases will be within reach.
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Introduction
Vaccination is one of the most successful and cost-effective
ways of improving public health and has been used to save
lives for at least two centuries. Traditional vaccine develop-
ment was largely based on Pasteur’s principles, which are to
‘isolate, inactivate, and inject’ the disease-causing agent,
hence producing vaccines composed of inactivated, live
attenuated or purified subunits of a microorganism [1]. How-
ever, sequencing of the first bacterial genome, Haemophilus
influenzae in 1995, and the arrival of the era of microbial ge-
nomics have led to many changes in vaccinology. The contin-
uing advances in genome sequencing technologies and
bioinformatics now enable researchers to explore a microor-
ganism’s ‘book of life’, its genome, for antigen discovery.
Microbial genomes contain the complete repertoire of possi-
ble antigens and are used as the starting point to capture
information for vaccine development. This process, known as
‘Reverse Vaccinology’ [2], was first proposed in 2000 based
on the identification of novel meningococcal vaccine candi-
dates from the genome sequence of a Neisseria meningitidis
serogroup B strain. The use of reverse vaccinology over the
last decade has changed the way vaccine development is
approached and this new era of vaccine research has been
referred to as a renaissance of vaccinology (Fig. 1).
The original idea behind reverse vaccinology was to start
in silico to screen the entire genome of a pathogen to identify
genes that encode proteins with the attributes of good vac-
cine targets, for example, proteins that are predicted to be
surface exposed and that are well conserved between strains.
These selected proteins are then expressed in Escherichia coli
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and used to immunize mice to enable evaluation of immuno-
genicity and protection based on the analysis of antisera by
flow cytometry, and in serum bactericidal activity and opso-
nophagocytosis assays or in animal models of infection. Over
the past decade, the methodologies used in reverse vaccinol-
ogy projects have progressed far beyond the original analysis
of a single meningococcal genome [3]. Improved sequencing
technologies have greatly increased the number of genomes
available and reverse vaccinology has evolved to include the
analysis of several genomes within a species (e.g. pan-geno-
mic analysis of group B streptococcus (GBS)) [4], between
closely related species (e.g. comparative-genomic analysis of
GBS, group A streptococcus (GAS) and Streptococcus pneu-
moniae) or between pathogenic and commensal members of
the same species (e.g. comparative/subtractive genomics of
E. coli) [5,6]. Furthermore, high throughput proteomic analy-
ses are now possible, as proteins and peptides can be easily
identified using data obtained by mass spectrometry to
search genome databases, and can provide important infor-
mation for vaccine development (e.g. analysis of the GAS
FIG. 1 Schematic overview of reverse vaccinology. Reverse vaccinology started with the analysis of a single genome of a meningococcus sero-
group B strain, and pan-genomics, comparative genomics and substractive genomics were subsequently used for various projects, with the incor-
poration of proteomics, molecular epidemiology and structural biology to further refine the process of antigen discovery. Furthermore, during
the process of vaccine development several new virulence factors have been identified, including the Neisseria meningitidis factor H binding pro-
tein (fHbp) and neisserial heparin-binding antigen (NHBA), as well as pili of group B streptococcus, group A streptococcus and Streptococcus
pneumoniae.
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surface proteome) [7,8]. Protein microarrays can also be
used to identify proteins expressed during host infection [9].
As other innovative fields of research have emerged, such as
immunoproteomics, structural biology and systems biology,
they have also been applied to vaccine development, and are
helping researchers to overcome the limits of conventional
approaches in the discovery and development of novel vac-
cines, especially against infectious diseases caused by diverse
and variable microorganisms [10–12].
In this review, we summarize the progress of over a dec-
ade of genome and proteome-based vaccinology, focusing on
several projects that have used reverse vaccinology as the
main approach for antigen discovery (see Fig. 2), including
vaccines against N. meningitidis serogroup B, for which an
application has been submitted for licensure in Europe, and
vaccines against GBS, GAS, S. pneumoniae and E. coli, which
are being analysed in preclinical studies.
Serogroup B Neisseria meningitidis—classic one-genome
reverse vaccinology
The development of a serogroup B Neisseria meningitidis
(MenB) vaccine represents the first example of the successful
application of reverse vaccinology [3,13–15]. Neisseria menin-
gitidis is a major cause of septicaemia and meningitis leading
to high mortality and morbidity worldwide, and MenB is the
predominant serogroup responsible for meningococcal dis-
ease in most of the developed world (reviewed in ref. 16).
Conventional MenB vaccine approaches have proved unsuc-
cessful, largely because the serogroup B capsular polysaccha-
ride is similar to host cell components and is poorly
immunogenic, but also because of the high degree of variabil-
ity of meningococcal major outer membrane proteins [17].
MenB reverse vaccinology became possible with the
sequencing of the first genome of a serogroup B N. meningiti-
dis strain (strain MC58) in 2000, as a result of the synergy
of three groups, the J. Craig Venter Institute (formerly
TIGR) USA, Novartis Vaccines and Diagnostics (formerly
Chiron Corporation) Italy, and Oxford University UK [18].
With the unravelling of the genome code of this pathogen,
researchers were able to select nearly 600 potential vaccine
candidates by in silico analysis. Following this, 350 recombi-
nant proteins were successfully expressed in E. coli and used
to immunize mice, from which 91 novel proteins were con-
firmed to be surface exposed by flow cytometry analysis,
and 28 proteins were found to induce bactericidal antibodies
[3]. After further analysis, a final four-component MenB
(4CMenB) vaccine was formulated, which consists of three
recombinant protein antigens (NHBA-GNA1030 and
GNA2091-fHbp fusion proteins and NadA) and outer mem-
brane vesicles from the strain used for the New Zealand
OMV vaccine (contains PorA 1.4) [13]. Using the meningo-
coccal genome, novel vaccine candidates were discovered
that have since been identified as important virulence fac-
tors. Factor H binding protein (fHbp) binds factor H (fH), a
key inhibitor of the complement alternative pathway, and
enables the meningococcus to evade killing by the innate
immune system [19,20]. Neisserial heparin binding antigen
(NHBA) also plays a role in serum resistance [21], and the
neisserial adhesin A (NadA) is important for bacterial–host
cell interactions [22,23].
FIG. 2 Timeline of a decade of reverse vaccinology. Vaccine projects that have used genomic-based and proteomic-based reverse vaccinology
approaches over the last decade are shown, along with their key outcomes: MenB, Nesseria meningitidis serogroup B; GBS, group B streptococ-
cus; GAS, group A streptococcus, Streptococcus pneumoniae; and pathogenic Escherichia coli. The rapid advancement of genome sequencing is also
highlighted, with only one bacterial genome available in 1995 and the human genome being completed in 2003; however, there are now more
than 11 500 genome sequencing projects underway and at least 2650 bacterial genome sequences available (http://genomesonline.org).
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Molecular epidemiological investigation revealed that the
main antigens fHbp, NHBA and NadA, can be classified into
three, fourteen and five variant groups, respectively [24].
Furthermore, this analysis revealed that prediction of vaccine
coverage was not possible on the basis of traditional menin-
gococcal typing systems [24], such as multi-locus sequence
typing or capsule-based serogrouping [16,25]. In the serum
bactericidal activity assay, which is the correlate of protec-
tion used for meningococcal vaccines [26], cross-reactivity
exists between NHBA variants [21,27] and the three main
NadA variants identified in hypervirulent strains [28]; how-
ever, little cross-protection is seen between fHbp variant 1
(present in the 4CMenB vaccine) and the other two fHbp
variant groups [29,30]. Furthermore, the level of expression
of these antigens varies between strains [21,29,31]. At this
point, it became apparent that a new typing system was
needed to predict the potential strain coverage of the
4CMenB vaccine, and the meningococcal antigen typing sys-
tem (MATS) was developed. MATS is a vaccine antigen-spe-
cific sandwich ELISA that measures the amount of each
antigen expressed by a strain and its immunological cross-
reactivity with the antigen present in the 4CMenB vaccine
[32]. MATS is correlated with killing of strains in the serum
bactericidal activity assay, and MATS analysis of large strain
panels from many countries predicted that adults and infants
immunized with the 4CMenB vaccine would be protected
from disease caused by 86% and 77% of the global MenB
strains, respectively [32–34].
Clinical trial data from studies with >1800 infants showed
that 4CMenB (commercial name Bexsero; Novartis Vaccines
and Diagnostics, Siena, Italy) is safe and induces a robust
immune response. Protective immune responses (human
serum bactericidal activity titres ‡1:5) were seen against ref-
erence MenB strains containing the vaccine antigens; at least
99% of participants produced antibodies that killed strains
44/76 (specific for fHbp) and 5/99 (specific for NadA), and
87% produced antibodies that killed strain NZ98/254 (spe-
cific for OMV PorA). MATS data together with a compre-
hensive clinical programme with 4CMenB has served as the
basis for submission for regulatory approval to the European
Medicines Agency [14,15,35–39].
Streptococcus agalactiae—pan-genome reverse vaccinology
Multigenome reverse vaccinology was applied to the gram-
positive pathogen Streptococcus agalactiae (GBS), based on
analysis of eight GBS genomes to address the sequence
diversity of this species [4,40]. Transmission of GBS mostly
occurs from mother to newborn during delivery, causing
sepsis, pneumonia and meningitis in the first month of life.
GBS also causes severe invasive infections in the elderly, in
pregnant women and in patients with underlying diseases
(reviewed in ref. [41]). There are nine GBS serotypes, distin-
guished by their capsular polysaccharide, and serotypes Ia, Ib,
II, III and V account for the majority of disease in the USA
[42]. The risk of neonatal infection is inversely proportional
to the maternal amounts of specific antibodies to capsular
polysaccharide [43,44] and capsular polysaccharide-conjugate
vaccines are safe and immunogenic in clinical trials [45,46].
However, there are a number of non-typeable GBS isolates
that would not be protected by these vaccines [46,47], and
efforts to develop vaccines based on conserved protein anti-
gens are in progress [41].
Because of the high level of diversity between GBS strains,
reverse vaccinology was applied to several genomes to
enable the total gene repertoire or ‘pan-genome’ of the spe-
cies to be screened for vaccine candidates. Analysis of eight
GBS genomes revealed a core genome of c.1806 genes pres-
ent in all strains, plus a dispensable genome of 907 genes
that are absent in one or more strains [40]. In silico screening
identified 589 predicted surface-exposed proteins, of which
396 were core genes and 193 were dispensable genes [4].
Of these, 312 were successfully expressed in E. coli and eval-
uated for their ability to mediate protection in a mouse
maternal immunization–neonatal pup challenge model. Four
proteins were found to be protective: GBS322 from the
core genome, as well as GBS67, GBS80 and GBS104, which
are present in the dispensable genome and would not have
been identified if only a single genome had been screened,
however, in combination they proved to be protective
against a large panel of strains [4].
Interestingly, three of the newly identified protective
GBS antigens were seen to assemble into pili, which are
long filamentous structures that extend from the bacterial
surface and play an important role in the virulence of many
pathogens [48]. Sequence analysis of a large panel of GBS
isolates revealed the presence of three pilus islands, PI-1,
PI-2a and PI-2b, and all strains characterized to date have
at least one, but often two, of the islands [48–50]. Each
island encodes a pilus composed of three structural pro-
teins containing an LPXTG motif, the backbone protein
(BP) and two ancillary proteins (AP1 and AP2), of which BP
and AP1 induce protective antibodies [4,49,50]. Moreover,
DNA sequence analysis has shown that the three subunits in
strains carrying the same island are highly conserved and
cross-protective, with the exception of BP-2a, which has six
non cross-protective variants [50]. Based on these data, a vac-
cine containing one component of each pilus (BP-1, BP-2b and
AP-2a) was tested and shown to elicit opsonophagocytic anti-
bodies in an in vitro opsonophagocytosis assay and provide a
high level of protection against a large panel of virulent strains
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from key serotypes in the maternal immunization/neonatal pup
challenge model [50].
Streptococcus pyogenes—comparative genomics and proteo-
mic-based reverse vaccinology
Streptococcus pyogenes (GAS) is a gram-positive pathogen that
causes disease ranging from uncomplicated pharyngitis to
life-threatening necrotizing fasciitis, toxic shock and rheu-
matic fever. Despite significant attempts, there is currently
no vaccine available against GAS [51,52].
Using comparative genomics and bioinformatics, five GAS
genomes were analysed for typical pilus regions, which were
identified by the presence of genes encoding proteins con-
taining the cell-wall attachment motif LPXTG that were also
closely linked with sortase enzymes. Three to five genes
coding for LPXTG-containing proteins were identified in the
various genomes and a combination of three recombinant
pilus proteins (Cpa, M1_128 and M1_130) was shown to
confer protection in mice against mucosal challenge with vir-
ulent GAS strains [53]. The GAS pili are encoded by nine
different gene clusters and are highly variable; however, it
was predicted that a vaccine combining 12 backbone variants
could provide protection against over 90% of circulating
GAS strains [54].
An innovative proteomic-based approach has also been
applied to GAS to specifically isolate and identify surface
proteins, termed the bacterial surface proteome or ‘surf-
ome’. Proteolytic enzymes were used to ‘shave’ the bacterial
surface, and the peptides released were analysed by mass
spectrometry and identified using the available GAS genome
sequences [8]. Seventy-two surface-exposed proteins were
identified in strain M1_SF370, the majority of which were
predicated by PSORT to be surface-associated and which
included most of the protective GAS antigens described to
date. Additional analysis of the highly virulent strain
M23_DSM2071, led to the identification of 17 surface-
exposed proteins, 14 of which were expressed in E. coli and
tested to determine their ability to mediate protection in a
mouse model. This approach led to the identification of one
new protective antigen (Spy0416), which is highly conserved
and a major cell surface component of >70% of the GAS
strains [8].
Streptococcus pneumoniae—comparative genomics and
reverse vaccinology
Several classical and genome-based approaches have been
applied to S. pneumoniae for identification of virulence factors
and vaccines antigens [55–57]. Streptococcus pneumoniae is a
gram-positive bacterium that causes significant human dis-
ease, including sepsis, meningitis, pneumonia, otitis media and
sinusitis, and it accounts for c.11% of mortality worldwide in
children under 5 years old [58]. Streptococcus pneumoniae can
be classified into more than 90 capsular serotypes, and multi-
valent capsule polysaccharide (Pneumovax 23, Merck, NJ,
USA.) and polysaccharide protein conjugate vaccines (7-
valent or 13-valent Prevnar; Pfizer, New York, NY, USA,
10-valent Synflorix, GlaxoSmithKline, Brentford, UK.) [59]
are currently available. However, many pneumococcal pro-
teins are being evaluated for use in a universal serotype-inde-
pendent vaccine, because of increasing antibiotic resistance
and limitations of polysaccharide vaccines, including poor
immunogenicity of unconjugated vaccines in infants, the com-
plexity and cost of protein conjugate vaccines, the variable
regional distribution of serotypes and the restricted coverage
of available vaccines [59], as well as the occurrence of sero-
type replacement after vaccination [60].
The availability of multiple pneumococcal genome
sequences combined with the increased understanding of pili
in GBS and GAS led to the discovery of pili in S. pneumoniae
and the investigation of pneumococcal pilus proteins as vac-
cine antigens [61,62]. Pneumococcal pili are involved in
adherence and virulence as well as in stimulating the host
inflammatory response [61–64]. Pilus 1 and pilus 2 are anti-
genically distinct and are encoded by two genomic pilus
islets, PI-1 and PI-2, that are present in about 30% and 16%
of pneumococcal clinical isolates, respectively [63,65]. Pilus 1
is encoded by the rlrA islet, and is composed of three subun-
its, a backbone protein (RrgB) and two ancillary proteins
(RrgA and RrgC) [55,61,62,66], whereas Pilus 2 consists of
the backbone protein PitB [63]. Active and passive immuniza-
tion with recombinant pilus subunits RrgA, RrgB and RrgC
showed protection against lethal challenge with strain TIGR4
[67]. Further molecular epidemiology investigations have
shown the presence of two variants of RrgA, both of which
elicit cross-protection [68].
Pathogenic Escherichia coli—subtractive genomics and
reverse vaccinology
Pathogenic E. coli are responsible for a range of infections,
and are classified as either extra-intestinal or intestinal path-
ogenic E. coli. The extra-intestinal pathogenic E. coli strains
are responsible for the majority of urinary tract infections
(UPEC strains) and are the second most common cause of
neonatal meningitis and sepsis (NMEC strains), whereas
intestinal strains are the major cause of travellers’ diarrhoea
and can cause more serious haemolytic uraemic syndrome
(reviewed in ref. [69]).
Comparative genome analysis and subtractive reverse
vaccinology, using the genomes of two NMEC strains, five
UPEC strains, one pathogenic avian E. coli strain and one
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non-pathogenic E. coli K12 strain, led to the identification of
230 antigens present in extra-intestinal pathogenic E. coli
strains but absent (or poorly conserved) in non-pathogenic
strains [5]. This approach was aided by the earlier character-
ization of outer membrane and secreted proteins by proteo-
mic analysis of outer membrane vesicles from pathogenic
E. coli strains [70–72]. Further analysis of candidates led to
the identification of nine potential vaccine antigens that, fol-
lowing immunization with the recombinant protein, were
able to induce protection in a mouse challenge sepsis model.
For the most protective antigen, ECOK1_3385, both active
immunization with the recombinant protein and passive
immunization with sera raised against this antigen provided
nearly complete protection from bacteraemia and mortality
in the mouse model of sepsis. ECOK1_3385 is widely distrib-
uted among E. coli pathotypes with amino acid sequence
identity ranging from 86% to 100%. Some of the novel pro-
tective antigens are also present in intestinal pathogenic
E. coli, suggesting the possibility of a broadly protective vac-
cine against pathogenic E. coli [5].
Conclusions and perspectives
Significant progress has been made in the field of vaccinology
during the era of genomics, and vaccines are set to have an
increasing impact on public health in the coming years. A
decade of genome-based and proteome-based reverse vacci-
nology, targeting bacterial pathogens including MenB, GBS,
GAS, S. pneumoniae and pathogenic E. coli, has resulted in the
discovery of numerous candidate vaccine antigens that are
undergoing preclinical development, in addition to the clinical
development of the 4CMenB vaccine (Fig. 2). The continual
advancements in genome sequencing technologies and the
approaches used to screen the genome and proteome of a
bacterial pathogen have greatly improved the efficiency and
time needed for antigen discovery. These advancements have
also improved antigen discovery and characterization for
eukaryotic pathogens, which often encode >10 000 genes
[73]. Genomics is also increasingly used to characterize vari-
ability between viral pathogens, which typically contain fewer
than ten genes [74].
Reverse vaccinology is now being applied to many bacterial,
viral and eukaryotic pathogens and has been successful in all
cases in providing novel antigens for the design of new vac-
cines [10–12]. Furthermore, the ability to improve candidate
antigens by rational design and structural vaccinology can pro-
vide increased protection against antigenically variable patho-
gens. For example, a structural vaccinology approach has been
used to address the sequence variability of the MenB vaccine
antigen fHbp, where a single antigen has been designed, which
could elicit broadly protective immunity against strains
expressing any fHbp variant, by grafting multiple immunodomi-
nant epitopes onto a single fHbp variant 1 molecule [75]. Sim-
ilarly, a synthetic GBS pilus antigen has been constructed
that comprises the protective domain of each of six vari-
ants of the backbone protein, BP-2a, to facilitate the
development of a broadly protective pilus-based vaccine
against GBS [76]. In addition, formulation of selected anti-
gens with appropriate adjuvants may also expand the pro-
tection provided against variable pathogens. In the coming
years, genomics will continue to contribute to vaccine
development as human genomics and systems biology
address questions aimed at understanding the types of
immune responses needed to control certain diseases, the
ways in which adjuvants direct the immune system and
the different outcome of vaccination in the population.
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